Peripheral Blood Immune Cell Composition After Autologous MSC Infusion in Kidney Transplantation Recipients
Transplant International · 2023
DOI: 10.3389/ti.2023.11329 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Transplant International, 2023. Verfasst von Sanne H Hendriks und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Leiden University Medical Center (LUMC), Leiden, Netherlands. Hauptthemen laut MEDLINE: Kidney Transplantation, Mesenchymal Stem Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.
Abstract (Originalsprache)
Tacrolimus is the backbone of immunosuppressive agents to prevent transplant rejection. Paradoxically, tacrolimus is nephrotoxic, causing irreversible tubulointerstitial damage. Therefore, infusion of mesenchymal stromal cells (MSC) 6 and 7 weeks post-transplantation was assessed to facilitate withdrawal of tacrolimus in the randomized phase II TRITON trial. Here, we performed detailed analysis of the peripheral blood immune composition using mass cytometry to assess potential effects of MSC therapy on the immune system. We developed two metal-conjugated antibody panels containing 40 antibodies each. PBMC samples from 21 MSC-treated patients and 13 controls, obtained pre-transplant and at 24 and 52 weeks post-transplantation, were analyzed. In the MSC group at 24 weeks, 17 CD4 + T cell clusters were increased of which 14 Th2-like clusters and three Th1/Th2-like clusters, as well as CD4+FoxP3+ Tregs. Additionally, five B cell clusters were increased, representing either class switched memory B cells or proliferating B cells. At 52 weeks, CCR7 + CD38 + mature B cells were decreased. Finally, eight Tc1 (effector) memory cytotoxic T cell clusters were increased. Our work provides a comprehensive account of the peripheral blood immune cell composition in kidney transplant recipients after MSC therapy and tacrolimus withdrawal. These results may help improving therapeutic strategies using MSCs with the aim to reduce the use of calcineurin inhibitors. Clinical Trial Registration : ClinicalTrials.gov , identifier NCT02057965.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Leiden University Medical Center (LUMC), Leiden, Netherlands.
- German Rheumatism Research Center (DRFZ), Berlin, Germany.
- Department of Internal Medicine (Nephrology) and Transplant Center, Leiden University Medical Center, Leiden, Netherlands.
- Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus University Medical Center, Leiden, Netherlands.
Förderung
- ZonMw
Zitieren
APA
Hendriks, S. H., Heidt, S., Schulz, A. R., de Fijter, J. W., Reinders, M. E. J., Koning, F., & van Kooten, C. (2023). Peripheral Blood Immune Cell Composition After Autologous MSC Infusion in Kidney Transplantation Recipients. Transplant International. https://doi.org/10.3389/ti.2023.11329
Vancouver
Hendriks SH, Heidt S, Schulz AR, de Fijter JW, Reinders MEJ, Koning F, et al. Peripheral Blood Immune Cell Composition After Autologous MSC Infusion in Kidney Transplantation Recipients. Transplant International. 2023. doi:10.3389/ti.2023.11329
BibTeX
@article{Hendriks2023,
author = {Hendriks, Sanne H and Heidt, Sebastiaan and Schulz, Axel R and de Fijter, Johan W and Reinders, Marlies E J and Koning, Frits and van Kooten, Cees},
title = {Peripheral Blood Immune Cell Composition After Autologous MSC Infusion in Kidney Transplantation Recipients},
journal = {Transplant International},
year = {2023},
doi = {10.3389/ti.2023.11329}
}
EUVIMED